Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca announces new research alliances

AstraZeneca announces new research alliances

22nd March 2013

AstraZeneca is strengthening its research capabilities with a pair of new strategic alliances announced this week.

The first of these will see the firm ally with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases, as well as cancer.

With this new method, the body is enabled to produce therapeutic proteins in vivo, meaning it could be used to combat a wide range of diseases that cannot be addressed using existing technology.

Meanwhile, AstraZeneca will also be setting up an integrated translational research centre for cardiovascular and metabolic disease and regenerative medicine in partnership with the Swedish medical university Karolinska Institutet.

Located in Stockholm, the centre will carry out studies that advance understanding of disease pathophysiology, while assessing new drug targets for AstraZeneca's two biotechnology business units.

Menelas Pangalos, executive vice-president of the innovative medicines and early development biotech unit at AstraZeneca, said this move "will speed our ability to translate groundbreaking research into the delivery of new medicines".ADNFCR-8000103-ID-801560717-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.